Gilead's Veklury (remdesivir) Receives the TGA's Approval to Treat Adults and Adolescents with Severe COVID-19 Symptoms
- The TGA authorization follows the recent data shared by EMA and Singapore Health Sciences Authority for remdesivir’s approval in EU- Singapore and- Japan for COVID-19 patients
- TGA’s approval was made within 2 weeks of the receipt of the submission while the provisional approval is based on preliminary data valid for 6 years. Additionally- the company plans filling full registration confirming the safety and efficacy of the drug to the TGA committee
- Remdesivir is an investigational drug targeted reduce hospitalization time for COVID-19 while the drug will be available for severely unwell- requiring oxygen or high-level support to breathe- and in-hospital care
Click here to read full press release/ article
Ref: Therapeutic Goods Administration | Image: Gilead
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].